Clinical Trials

Anatomic Stage I Breast Cancer AJCC v8

NCT06348134 2026-02-17

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

74 enrolled

Breast Neoplasms

NCT07158021 2026-02-13

Leuprolide and Goserelin for Ovarian Function Suppression in Pre- or Peri-menopausal Women With Breast Cancer, OFS Trial

75 enrolled

Breast Neoplasms

NCT02624973 2026-02-12

PETREMAC

200 enrolled

Breast Neoplasms

NCT05122377 2026-01-06

RWE About QOL and Compliance of Patients With OFS in China

Completed

562 enrolled

Breast Neoplasms, Patient Compliance

NCT01723774 2025-12-09

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

84 enrolled 17 charts

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07179939 2025-09-18

Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study

288 enrolled

HER2-positive Breast Cancer

NCT02476786 2025-07-28

Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score

50 enrolled

Breast Neoplasms

NCT06953882 2025-07-14

SELECT

140 enrolled

HER2 Negative Breast Cancer

NCT02430103 2024-12-12

Study of Preservation of Ovarian Reserve During Chemotherapy for Young Breast Cancer Patients

Active not recruiting

349 enrolled

Breast Neoplasms

NCT05594095 2024-10-04

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

620 enrolled

Breast Neoplasms

NCT05163106 2024-08-02

NEOLETRIB

85 enrolled

Breast Neoplasms

NCT05720260 2024-06-10

Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC

42 enrolled

Phase 3 Active not recruiting

Breast Neoplasms

NCT02344472 2024-06-04

Detect V / CHEVENDO (Chemo vs. Endo)

271 enrolled

Breast Neoplasms

NCT03007979 2024-03-20

Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer

55 enrolled 15 charts

Breast Neoplasms

NCT03664895 2023-12-04

Density Lowering Effect of "OFS Add on to TMX"(DELFINO Trial)

224 enrolled

Breast Cancer Invasive

NCT05800197 2023-04-06

NEMO

Unknown

300 enrolled

Breast Neoplasms

NCT03447132 2023-03-10

SAFIA

354 enrolled

Breast Neoplasms

NCT02914158 2023-01-17

ASPAIT

680 enrolled

Breast Neoplasms

NCT01989780 2022-08-04

BOOSTER

160 enrolled

Breast Neoplasms

NCT05439499 2022-07-06

This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.

434 enrolled

Advanced Breast Cancer

NCT05438810 2022-07-05

This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.

312 enrolled

Advanced Breast Cancer

NCT05253066 2022-02-23

Chidamide Combined With Exemestane (+/- Goserelin) Versus Neoadjuvant Chemotherapy in Patients of Stage II-III HR-positive/HER2-negative Breast Cancer

Phase 2/3 Unknown

130 enrolled

Breast Neoplasms

NCT02626507 2022-02-09

Phase I Study of Combination of Gedatolisib With Palbociclib and Faslodex in Patients With ER+/HER2- Breast Cancer

Phase 1 Unknown

18 enrolled

Breast Neoplasms

NCT02586675 2022-01-21

TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer

Phase 1 Completed

7 enrolled 8 charts

Breast Neoplasms, Neoplasm Metastasis, Breast Neoplasms, Male

NCT05131893 2021-11-23

Neoadjuvant Treatment of Breast Cancer

Not yet recruiting

300 enrolled

Breast Neoplasms

NCT02907918 2021-09-29

PALTAN

Phase 2 Terminated

26 enrolled 8 charts

Breast Neoplasms

NCT02603679 2021-08-03

PREDIX LumB

181 enrolled

Breast Neoplasms

NCT02518191 2021-06-11

Effects of GnRHa on Ovarian Function Against Chemotherapy-induced-gonadotoxicity

345 enrolled 9 charts

Breast Neoplasms

NCT02592083 2020-07-07

PREDIX LumA

10 enrolled

Breast Neoplasms

NCT02532400 2020-03-11

COMPETE

Phase 3 Terminated

21 enrolled

Breast Neoplasms

NCT00186121 2019-10-07

Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women

35 enrolled 11 charts

Breast Neoplasms

NCT01638247 2018-09-19

MALE

56 enrolled

Breast Neoplasms, Male

NCT03591549 2018-07-23

Fulvestrant in Metastatic Breast Cancer

Phase 4 Unknown

30 enrolled

Breast Neoplasms

NCT03444025 2018-02-23

NeoGONT

Phase 2 Unknown

180 enrolled

Triple Negative Breast Neoplasms

NCT03373708 2017-12-18

Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer

Phase 2/3 Unknown

200 enrolled

Breast Diseases, Breast Neoplasms

NCT02483767 2017-10-17

POF

98 enrolled

Breast Neoplasms

NCT01266213 2017-05-01

FLAG

Phase 2 Unknown

147 enrolled

Breast Neoplasms

NCT00429403 2016-05-09

Goserelin Acetate Study for Ovarian Function in Patients With Primary Breast Cancer

Phase 3 Terminated

1 enrolled 3 charts

BreastGynecologic

Breast Neoplasms, Primary Ovarian Insufficiency

NCT00010010 2016-03-11

Exemestane Plus Goserelin in Treating Premenopausal Women With Metastatic Breast Cancer

Breast Neoplasms

NCT01530607 2016-02-25

Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer

416 enrolled

Breast Neoplasms

NCT01368263 2015-04-03

Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer

Phase 2 Terminated

8 enrolled 5 charts

Breast Neoplasms

NCT00053911 2014-12-16

Combination Chemotherapy Compared With Observation After Surgery in Treating Women With Relapsed Nonmetastatic Breast Cancer

Phase 3 Terminated

Breast Neoplasms

NCT02132390 2014-06-04

Adjuvant Toremifene With or Without Goserrelin in Premenopausal Women With Stage I-IIIA, Hormonal Receptor Positive Breast Cancer Accompanied With or Without Chemotherapy Induced Amenorrhoea

300 enrolled

Breast Neoplasms

NCT02072512 2014-02-26

PROOF

Phase 2 Unknown

180 enrolled

Breast Neoplasms

NCT01240928 2013-08-20

MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer

Phase 1 Withdrawn

Breast Neoplasms

NCT01240941 2013-08-20

Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer

Phase 2 Withdrawn

Breast Neoplasms

NCT01013506 2013-05-23

Phase 2, Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-sensitive Metastatic Breast Cancer

Phase 2 Withdrawn

Breast Neoplasms

NCT00498901 2013-05-09

Letrozole and Goserelin or Leuprolide in Treating Premenopausal Estrogen Receptor-Positive Patients With Stage IV Breast Cancer

Phase 2 Terminated

1 enrolled